BULFINCH LEASES 60 HAMILTON STREET TO COVID-19 VACCINE DEVELOPER BIONTECH
BOSTON, MA – July 29, 2021
Bulfinch today announced it has leased 100 percent of its 60 Hamilton Street property in Cambridge, MA to BioNTech, a German immunotherapy company specializing in the treatment of cancer and other serious diseases.
BioNTech focuses on a range of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Most recently, BioNTech partnered with Pfizer (an existing Bulfinch tenant) to co-develop the COVID-19 vaccine, which has been instrumental in addressing the pandemic worldwide. Bulfinch leveraged its life science portfolio to help BioNTech satisfy its rapidly emerging space needs resulting from the immunotherapy company’s recent successes surrounding its COVID-19 vaccine development efforts.
60 Hamilton Street is a two-story office and life science building located in the heart of Cambridge near the MBTA Red Line, MIT, and Harvard, and is in close proximity to BioNTech’s COVID-19 vaccine development partner Pfizer, a longtime tenant at Bulfinch’s Osborn Triangle campus in Cambridge. Situated amidst the Kendall Square life science and biotech hub, BioNTech’s neighbors at 60 Hamilton Street include Abbvie, Intellia Therapeutics, Fulcrum Therapeutics, SmartLabs, Acceleron, Agios, Blueprint Medicines, Takeda, and Sumitomo Dainippon Pharma Oncology, among others.
Originally built in 1925 and recently renovated in 2016, 60 Hamilton Street features brick and beam light-filled interiors that create a unique aesthetic with modern design features. Set in an amenity convenient location, the building provides a variety of walkable shopping options and includes a bike rack area, showers, and on-site parking along with additional garage-parking options nearby.
“We are thrilled to welcome a distinguished company such as BioNTech as a Bulfinch tenant,” stated Mike Wilcox, SVP, Director of Leasing at Bulfinch. “Bulfinch continues to expand our life science portfolio and seek partnerships with tenants like BioNTech that contribute to advancing the groundbreaking research and discovery taking place in Greater Boston to combat serious diseases on a global scale.”
Bulfinch’s SVP, Director of Leasing, Mike Wilcox worked closely with Colliers to represent Bulfinch for this transaction. The Colliers broker team included Evan Gallagher, Executive Vice President; Curtis Cole, Executive Vice President; Tim Allen, Assistant Vice President; and Caitlin Mahoney, Life Science Advisor. CBRE New England represented the tenant with Jonathan Varholak, Vice Chairman and McKenna Teague, Vice President leading the broker team.